 |
9 Products |  |
120 Diseases | | 9 Products |
|
46 Trials |  |
2133 News |  |
| «12345678910111213...2930» |
- Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Enrollment change, Trial termination: Evaluation of Testosterone Nasal Gel in Hypogonadal Boys (clinicaltrials.gov) - Oct 26, 2023
P1, N=8, Terminated, Sponsor: Acerus Biopharma Inc.
N=20 --> 8 | Unknown status --> Terminated; Lack of patients and commercial reasons
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 18, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=20 --> 8 | Unknown status --> Terminated; Lack of patients and commercial reasons Trial completion date: Apr 2024 --> Sep 2024
- | Ovastat (treosulfan) / Medac, Medexus, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
New P3 trial: OPTISAGE: Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor (clinicaltrials.gov) - Oct 13, 2023
P3, N=324, Not yet recruiting, Sponsor: Assistance Publique - H
- || Obnitix (MSC-FFM) / Medac
New P2 trial, Stroma: BALDER: Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (clinicaltrials.gov) - Oct 9, 2023
P2, N=48, Not yet recruiting, Sponsor: medac GmbH
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. (Pubmed Central) - Oct 5, 2023
These multinational data confirm the excellent curative capacity of MSD HSCT with myeloablative conditioning. Both conditioning regimens yielded excellent OS, low rates of acute and chronic GVHD, and low rates of graft failure.
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Reduced toxicity conditioning and a high CD34 cell dose can achieve full donor chimerism in DOCK8 deficiency. (Pubmed Central) - Oct 2, 2023
We are able to report that by using the aforementioned novel strategy, we achieved excellent transplant outcomes in the first cohort of high-risk patients with DOCK8 deficiency from India. High CD34 cell dose and reduced toxicity conditioning can achieve full donor chimerism in DOCK8 deficiency.
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Pretreatment with Rituximab probably increases the risk of occurrence of veno-occlusive disease in patients with aggressive lymphoma after allogeneic hematopoietic stem cell transplantation (Hall 4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1533;
We suspect rituximab as a risk factor for VOD after SCT. More studies are required to confirm our findings.
- Ovastat (treosulfan) / Medac, Medexus
Comparable outcomes for Fludarabine/TBI versus Fludarabine/Treosulfan conditioning prior to allogeneic stem cell transplantation (Allo-SCT) in AML and MDS patients. (Hall E) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1339;
Given that our single center analysis was not biased by effects attributable to different center policies, our data verified favorable survival outcomes with low rates of relapse or death in CR for intermediate or high-risk AML/MDS patients undergoing alloSCT. No significant differences were found between FluTBI and FluTreo conditioning therapy.
- Ovastat (treosulfan) / Medac, Medexus
Upfront allogeneic hematopoietic stem cell transplantation for patients with MDS (X4) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1305;
TRM (35%) esp. infectious related complications remain a problem, mainly in the first year after transplantation.
- Ovastat (treosulfan) / Medac, Medexus
Treatment of CMML in German stem cell transplantation centers (Hall F) - Sep 30, 2023 - Abstract #DGHO2023DGHO_620;
Yet, the exact modalities of HCT are handled differently. Further studies are warranted to identify which HCT regimens are associated with most favorable outcomes.
- Ovastat (treosulfan) / Medac, Medexus
Conditioning regimen with Fludarabin/Treosulfan compared to Busulfan/Cyclophosphamid prior to allogeneic stem cell transplantation in younger patients with AML and MDS: a single center retrospective analysis (Hall E) - Sep 30, 2023 - Abstract #DGHO2023DGHO_575;
The tendency towards a more favorable OS within the Bu/Cy group could be partially explained by a higher rate of active disease and older patients in the Flu/Treo group. Therefore, a randomized, prospective trial is needed to compare the Flu/Treo conditioning regimen with MAC.
- Keytruda (pembrolizumab) / Merck (MSD)
Sustained complete remission with oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab (Hall B) - Sep 30, 2023 - Abstract #DGHO2023DGHO_568;
Sustained CR was achieved over 9 months after initiation of MEPED therapy. Further studies on a larger patient cohort should be performed.
- || Ovastat (treosulfan) / Medac, Medexus
Review, Journal: Haematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. (Pubmed Central) - Sep 28, 2023
Since then, refinements in transplant technique, donor selection, conditioning regimens, and graft engineering have widened the option of HSCT to most patients with CGD. This review charts the progress made in HSCT for CGD.
- || Review, Journal, IO biomarker, Metastases: Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies. (Pubmed Central) - Sep 28, 2023
Lapitinib, neratinib and tucatinib have been approved for HER2-positive metastasis patients, however clinical trials are currently ongoing to optimize combined strategies, to reduce toxicity, and to better define the useful setting. Clinical research should be strengthened along with the discovery and validation of new biomarkers, as well as a deeper understanding of drug resistance and action mechanisms.
- oNKord (inaleucel) / Glycostem, Medac, Korea Kolmar
Single-cell transcriptomics, proteomics and in vitro cytotoxicity of allogeneic cryopreserved natural killer cell therapy GTA002 identify potent effector signatures (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_746;
P1/2
Clinical research should be strengthened along with the discovery and validation of new biomarkers, as well as a deeper understanding of drug resistance and action mechanisms. Conclusions In summary, this research contributes to the advancement of NK cell therapies by generating a deep understanding of the cells
- oNKord (inaleucel) / Glycostem, Medac, Korea Kolmar
Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_694;
P1/2
Addition of cytokine support further enhanced both baseline cytotoxicity as well as ADCC, leading to complete eradication of the SKOV-3 tumor cells. Conclusions Overall, the enhancement of the inherent potency of GTA002 by harnessing ADCC through combination therapy with mAbs achieved efficient Ag-specific responses demonstrating the great potential of multimodal targeting against a variety of challenging cancers using a highly safe
- | Ovastat (treosulfan) / Medac, Medexus
Journal, Post-transplantation: Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. (Pubmed Central) - Sep 25, 2023
Leukemia-free survival, overall survival, and GVHD-free, relapse-free survival was 65% versus 68% (P = 0.6), 73% versus 76% (P = 0.5), and 54% versus 53% (P = 0.8) in TBF versus Treo, respectively. In conclusion, we did not find a significant difference between the 2 conditioning in the present study; Treo and TBF represent 2 valid alternative regimens for haplo-HSCT with PTCy for AML in remission.
- || Ovastat (treosulfan) / Medac, Medexus
PK/PD data, Journal: Population pharmacokinetic modeling of treosulfan and rationale for dose recommendation in children treated for conditioning prior to allogeneic hematopoietic stem cell transplantation. (Pubmed Central) - Sep 25, 2023
In conclusion, we did not find a significant difference between the 2 conditioning in the present study; Treo and TBF represent 2 valid alternative regimens for haplo-HSCT with PTCy for AML in remission. The final model described an effect of the body surface area (BSA) on CL, V1, V2, and Q. The final model resulted in a modified dose recommendation for children and advises treosulfan doses of 10
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea? (Pubmed Central) - Sep 16, 2023
The final model described an effect of the body surface area (BSA) on CL, V1, V2, and Q. The final model resulted in a modified dose recommendation for children and advises treosulfan doses of 10 This study suggests that Treo/Flu conditioning may be an alternative to Bu/Flu regimen in elderly patients with high-risk who are not suitable for standard conditioning.
- | busulfan / Generic mfg.
Journal: Improved Outcome Following Busulfan-Based Conditioning in Children with Functional Neutrophil Disorders Undergoing Hematopoietic Stem Cell Transplant from HLA-Matched Donors. (Pubmed Central) - Sep 14, 2023
There was no effect of conditioning regimen on overall survival, as all 8 patients that proceeded to a second busulfan-based HSCT were salvaged. We recommend giving patients with CGD and LAD fully myeloablative conditioning with either a busulfan-based regimen or the combination of treosulfan, fludarabine, and thiotepa.
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 6, 2023
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
We recommend giving patients with CGD and LAD fully myeloablative conditioning with either a busulfan-based regimen or the combination of treosulfan, fludarabine, and thiotepa. Trial completion date: Jul 2023 --> Jun 2024
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience. (Pubmed Central) - Sep 4, 2023
Trial completion date: Jul 2023 --> Jun 2024 No abstract available
- Ovastat (treosulfan) / Medac, Medexus
Treatment of uveal melanoma patients with gemcitabine and treosulfan: a retrospective analysis. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_3223;
Adjustments to the treatment dose are necessary in case of adverse events under therapy. Further investigations are needed to show which patients benefit from initial dose reduction in the treatment.
- | Ovastat (treosulfan) / Medac, Medexus
Retrospective data, Journal: Treosulfan-based conditioning regimen in pediatric hematopoietic stem cell transplantation: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). (Pubmed Central) - Aug 19, 2023
The treosulfan-based radiation-free conditioning regimen is feasible, achieving a high engraftment rate and 5-year overall survival. A treosulfan-based conditioning regimen is an emerging option for the first HSCT in non-malignant diseases.
- | Ovastat (treosulfan) / Medac, Medexus
Journal: The impact of Treosulfan-based conditioning for inborn errors of immunity: Is dose monitoring crucial? (Pubmed Central) - Aug 3, 2023
The AUC of the treosulfan dose was not associated with poorer late outcomes. Treosulfan is an agent that can be used safely in the IEI patient group,
- || Ovastat (treosulfan) / Medac, Medexus
Retrospective data, Review, Journal: Treosulfan Versus Busulfan-based Conditioning in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis. (Pubmed Central) - Aug 1, 2023
A marginal improvement in survival was noted with treosulfan but the results remained unstable. Future randomized controlled trials are needed to provide better evidence.
- ||| Ovastat (treosulfan) / Medac, Medexus, Campath (alemtuzumab) / Sanofi, Zinbryta (daclizumab) / Biogen, AbbVie
Journal, Adverse events, Real-world evidence, Real-world: A Real-World Disproportionality Analysis of Drug-Induced Immune Hemolytic Anemia in the FDA Adverse Event Reporting System. (Pubmed Central) - Jul 31, 2023
Our study identified the most common drugs that could induce DIIHA in adults and children, as well as the respective ROR and PRR value to discover new drug signals. This study provides references to clinicians for the management of rare DIIHA.
- Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial (Bilbao Auditorium - NCC) - Jul 27, 2023 - Abstract #ESMO2023ESMO_799;
P3
PC could be either trastuzumab combined with capecitabine or vinorelbine or eribulin or lapatinib plus capecitabine...The final OS results confirm a trend towards a numerically prolonged OS (statistically non-significant) in the T-Duo group compared with PC group. Safety was aligned with the primary analysis, with no new signals identified.
- | Retrospective data, Journal: ?? /CD19 -depleted haploidentical stem cell transplantation for children with acute leukemia: Is there a protective effect of increased ?? T-cell content in the graft? (Pubmed Central) - Jul 24, 2023
?? /CD19 -depleted haploidentical hematopoietic stem cell transplantation can offer long-term remission for children with acute leukemia with minimal graft-versus-host disease.
- | oNKord (GCT NK cells) / Glycostem, Medac, Korea Kolmar
Journal: Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34 progenitor cell-derived NK cells. (Pubmed Central) - Jul 10, 2023
Umbilical cord blood (UCB) CD34 progenitor cell-derived natural killer (NK) cells exert efficient cytotoxicity against various melanoma cell lines...Strikingly, combinatorial receptor blocking led to more pronounced inhibition of cytotoxicity (up to 95%) than individual receptor blocking, especially in combination with TRAIL-blocking, suggesting synergistic cytotoxic NK cell activity via engagement of multiple receptors which was also confirmed in a spheroid model. Importantly, lack of NK cell-related gene signature in metastatic melanomas correlates with poor survival highlighting the clinical significance of NK cell therapies as a promising treatment for high-risk melanoma patients.
- || Ovastat (treosulfan) / Medac, Medexus
Clinical, Journal: Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). (Pubmed Central) - Jul 8, 2023
Furthermore, conditioning regimen was the only independent predictor of LFS, OS, and GVHD-free/relapse-free survival. Therefore, our real-world multicenter study suggests that FT14 is associated with better outcomes in primary refractory/relapsed AML.
- || Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion, Enrollment change, Combination therapy, Metastases: Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors (clinicaltrials.gov) - Jul 5, 2023
P1, N=32, Completed, Sponsor: Byondis B.V.
Therefore, our real-world multicenter study suggests that FT14 is associated with better outcomes in primary refractory/relapsed AML. Active, not recruiting --> Completed | N=120 --> 32
- | Venclexta (venetoclax) / Roche, AbbVie, Ovastat (treosulfan) / Medac, Medexus, Amsidine (amsacrine) / Kyowa Kirin
Enrollment open: Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (clinicaltrials.gov) - Jul 3, 2023
P1/2, N=38, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Active, not recruiting --> Completed | N=120 --> 32 Not yet recruiting --> Recruiting
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma. (Pubmed Central) - Jun 22, 2023
However, female patients had a significantly higher AUC (p = 0.007) and peak value (p = 0.001), and the higher values were associated with longer hospitalizations. (4) Treatment consolidation with TreoMel HDCT demonstrated a promising efficacy and safety profile in our cohort of MM patients and deserves further investigation in prospective studies.
- | Onconase (ranpirnase) / Orgenesis, Leidos, Spectrila (asparaginase Escherichia coli) / Medac
Journal: Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product. (Pubmed Central) - Jun 19, 2023
(4) Treatment consolidation with TreoMel HDCT demonstrated a promising efficacy and safety profile in our cohort of MM patients and deserves further investigation in prospective studies. In the present study, we compared a recombinant E. coli-derived ASNase marketed in Europe (Spectrila
- | Ovastat (treosulfan) / Medac, Medexus
Journal: Non-osteopenic Bone Pathology After Allo-hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity. (Pubmed Central) - Jun 19, 2023
Non-osteopenic bone pathology in long-term survivors of allo-HSCT for IEI is not rare. Most patients did not present with complaints until at least 5
- | Ovastat (treosulfan) / Medac, Medexus, Jakafi (ruxolitinib) / Novartis, Incyte
Journal: Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: A pilot experience. (Pubmed Central) - Jun 18, 2023
In a small cohort of mostly ruxolitinib pre-treated patients, SI and treosulfan-based conditioning appeared a safe and effective tool to reduce spleen dimensions and ameliorate symptoms. Future prospective studies with adequate sample size are warranted to further investigate the usefulness and safety of this approach in MF.
- | Ovastat (treosulfan) / Medac, Medexus
Retrospective data, Journal: Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. (Pubmed Central) - Jun 9, 2023
Univariate analysis by age group demonstrated a higher NRM exclusively in patients ?55 years of age treated with FluTBI compared to FluTreo (27.6% vs. 5.8%, p?=?0.02), while a similarly low NRM was observed in patients <55 years in both groups (6.0% vs. 4.7%, p?=?ns). We conclude that both conditioning regimens are effective and safe, but FluTBI may better be reserved for younger patients below the age of 55 years.
- ||||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion, Trial completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 25, 2023
P3, N=436, Completed, Sponsor: Byondis B.V.
We conclude that both conditioning regimens are effective and safe, but FluTBI may better be reserved for younger patients below the age of 55 years. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 23, 2023
P3, N=669, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022 Trial completion date: Jun 2023 --> Apr 2024
- Gamifant (emapalumab) / SOBI
EMAPALUMAB TREATMENT FOLLOWED BY HEMATOPOIETIC STEM CELL TRANSPLANTATION IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS COMPLICATED BY RECURRENT MACROPHAGE ACTIVATION SYNDROME () - May 19, 2023 - Abstract #EULAR2023EULAR_3188;
Treatment with high dose of intravenous (IV) methylprednisolone (mPDN) and oral cyclosporine (CYC) was started with progressive improvement...The conditioning regimen was based on a Thiotepa-Treosulfan-Fludarabine scheme...Conclusion This case provides further evidence of the efficacy of emapalumab in MAS [1], of the potential benefit of HSCT in difficult sJIA patients [2]. Notably, full control of inflammatory activity with emapalumab and anakinra may help to obtain a successful HSCT and reduce the risk of rejection.
- | Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion date, Combination therapy, Metastases: Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors (clinicaltrials.gov) - May 16, 2023
P1, N=120, Active, not recruiting, Sponsor: Byondis B.V.
Notably, full control of inflammatory activity with emapalumab and anakinra may help to obtain a successful HSCT and reduce the risk of rejection. Trial completion date: Dec 2023 --> Jun 2023
- ||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion, Metastases: SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma (clinicaltrials.gov) - May 16, 2023
P2, N=64, Completed, Sponsor: Byondis B.V.
Trial completion date: Dec 2023 --> Jun 2023 Active, not recruiting --> Completed
- || Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Trial completion date, Trial primary completion date, Adverse events: A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections (clinicaltrials.gov) - May 12, 2023
P4, N=200, Active, not recruiting, Sponsor: University of Miami
Active, not recruiting --> Completed Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
- Ovastat (treosulfan) / Medac, Medexus
ALLOGENEIC HSCT OUTCOMES IN SIX PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER TREATED WITH CHEMOTERAPY AND PARP INHIBITORS () - May 12, 2023 - Abstract #EHA2023EHA_3224;
The results obtained are in line with pts with AML with known high-risk features such as Tp53, RUNX1 and unfavorable karyotypes. The previous history of PARPi exposure in association with platinum-based chemotherapy in pts with OC did not clearly impact on allo-HSCT outcomes and should not be considered as a prohibitive factor for intensive treatment and allo-HSCT.
- azacitidine / Generic mfg.
AZACYTIDINE AND ALLOGENOUS STEM CELL TRANSPLANTATION IN LATE- ONSET ERYTHROPOIETIC PROTOPORPHYRIA () - May 12, 2023 - Abstract #EHA2023EHA_2918;
The symptomatic impact of EPP can be substantial and indicate treatment by itself. We saw rapid normalization of PPIX levels and a relief of photosensitivity post-Aza
- Ovastat (treosulfan) / Medac, Medexus, Kymriah (tisagenlecleucel-T) / Novartis
TREATMENT OF POST-TRANSPLANT RELAPSE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH BCP ALL USING CD19-CAR-T: A EUROPEAN RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA (Panorama 3) - May 12, 2023 - Abstract #EHA2023EHA_904;
Early loss of CAR-T cells may be a reflection of inferior T-cell effector function, i.e. sub- potent starting material for CAR-T manufacturing, early after HSCT. These findings may become relevant for further clinical decision making.
- | Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Journal: UTP11 deficiency suppresses cancer development via nucleolar stress and ferroptosis. (Pubmed Central) - May 12, 2023
In this study, we found that UTP11 plays an important role in the biosynthesis of 18S ribosomal RNAs (rRNA) by binding to the pre-rRNA processing factor, MPP10...On the other hand, UTP11 deficiency represses the expression of SLC7A11 by promoting the decay of NRF2 mRNA, resulting in reduced levels of glutathione (GSH) and enhanced ferroptosis. Altogether, our study uncovers a critical role for UTP11 in maintaining cancer cell survival and growth, as depleting UTP11 leads to p53-dependent cancer cell growth arrest and p53-independent ferroptosis.
- | Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Trial completion date, Trial primary completion date: The Effects of Natesto For Treatment Of Hypogonadism (clinicaltrials.gov) - May 11, 2023
P1, N=40, Not yet recruiting, Sponsor: Baylor College of Medicine
Altogether, our study uncovers a critical role for UTP11 in maintaining cancer cell survival and growth, as depleting UTP11 leads to p53-dependent cancer cell growth arrest and p53-independent ferroptosis. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Ovastat (treosulfan) / Medac, Medexus
Enrollment open: Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi (clinicaltrials.gov) - May 8, 2023
P2, N=120, Recruiting, Sponsor: University Hospital Inselspital, Berne
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting